GD Culture Group Ltd — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GD Culture Group Ltd filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $153.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $25.03M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $591.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $19.58M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.45M | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $38.75M | Apr 1, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $55.5K | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $8.25M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $570.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $562.2K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $333.9K | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $19.52M | Apr 1, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($186.88M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($13.84M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($12.52M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($30.82M) | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | ($26.97M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.51M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($16.83M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.45M | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $4.21M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($541.6K) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.46M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($14.16M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($11.99M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($414.2K) | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | ($19.55M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($496.8K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($289.4K) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($413.9K) | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $7.45M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($627.6K) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $797.5K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.07M | Mar 18, 2025 |
| FY2020 | Dec 31, 2020 | $0 | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | $351.8K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $261.0K | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $18.1K | Apr 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.24M | Jul 22, 2024 |
| FY2023 | Dec 31, 2022 | $414.2K | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | $19.55M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $1.17M | Apr 17, 2020 |
| FY2019 | Dec 31, 2018 | $747.8K | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.80M | Apr 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.84M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($5.68M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($13.24M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($886.2K) | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | ($5.51M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.1K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $759.5K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($2.04M) | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | ($426.4K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($386.8K) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $14.2K | Mar 18, 2025 |
| FY2021 | Dec 31, 2021 | $308.8K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $72.8K | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $3.5K | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.9K | Apr 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $670.16M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.73M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $14.21M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.80M | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | $50.54M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $25.14M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $22.45M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $32.85M | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $48.57M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $50.28M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.02M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.73M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.05M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $333.8K | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | $18.46M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.22M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $16.49M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $13.49M | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $21.32M | Apr 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $667.86M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($281.7K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $8.35M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.47M | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | $32.08M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $21.91M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $5.96M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $19.36M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $27.25M | Apr 17, 2020 |
| FY2017 | Dec 31, 2016 | $10.03M | Apr 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $2.19M | Jul 22, 2024 |
| FY2023 | Dec 31, 2021 | $6.59M | Jul 22, 2024 |
| FY2021 | Dec 31, 2020 | $11.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.29M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $7.39M | Apr 17, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($270.07M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($83.19M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($69.36M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($56.84M) | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | ($26.02M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $951.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.56M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $15.27M | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | $13.82M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($775.8K) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $456.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $22.5K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $5.18M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $389.1K | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | $14.59M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $998.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.48M | Mar 26, 2021 |
| FY2020 | Dec 31, 2018 | $726.7K | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $461.9K | Apr 17, 2020 |
| FY2017 | Dec 31, 2016 | $150.3K | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2023 | Dec 31, 2023 | (3) | Jul 22, 2024 |
| FY2023 | Dec 31, 2022 | (20) | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | (20) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | 0 | Apr 17, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (20) | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | (20) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.32M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 11.17M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 5.45M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 1.84M | Jul 22, 2024 |
| FY2022 | Dec 31, 2021 | 1.54M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 29.18M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 20.82M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 19.90M | Apr 17, 2020 |
| FY2018 | Dec 31, 2017 | 17.99M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 2.56M | Apr 2, 2018 |